Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification
Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
Intravacc appoints three Supervisory Board members
Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021
Intravacc publishes positive phase I Shigella conjugate vaccine data
Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer
Intravacc 2.0
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
